SCHEMBL8264285

SCHEMBL8264285

CC(C)(C)OC(=O)N1CCC(c2cccc(O)c2)=C(C(=O)O)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.54
NR1H2 P55055 1/20 0.45
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
SRC P12931 1/20 0.42
ABL2 P42684 1/20 0.42
UCHL1 P09936 1/20 0.41
ADORA1 P30542 1/20 0.40
MAPK1 P28482 1/20 0.40
USP30 Q70CQ3 3/20 0.39
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
GPR119 Q8TDV5 2/20 0.38
PDK4 Q16654 1/20 0.38
F12 P00748 1/20 0.37
NAMPT P43490 1/20 0.37
PARP1 P09874 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
PARP2 Q9UGN5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8264160 0.90 USP30 (0.47) ESR2NR1H2UCHL1ADORA1MAPK1
SCHEMBL8253723 0.89 ESR2 (0.52) ESR2NR1H2ABL1EGFRSRC
SCHEMBL951850 0.88 ESR2 (0.48) ESR2NR1H2UCHL1ADORA1MAPK1
SCHEMBL13617452 0.88 ESR2 (0.51) ESR2NR1H2ABL1EGFRSRC
SCHEMBL7047941 0.88 SLC6A3 (0.47) ESR2NR1H2UCHL1ADORA1MAPK1
SCHEMBL13490542 0.88 ESR2 (0.45) ESR2NR1H2UCHL1ADORA1MAPK1
SCHEMBL8265146 0.88 ESR2 (0.45) ESR2NR1H2UCHL1ADORA1MAPK1
SCHEMBL1752020 0.87 MGAT2 (0.48) ESR2NR1H2ABL1EGFRSRC
SCHEMBL8264299 0.84 ESR2 (0.47) ESR2NR1H2ABL1EGFRSRC
SCHEMBL8264295 0.82 MGAT2 (0.42) ESR2NR1H2ABL1EGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029647-A1 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES NOVARTIS AG (CH) 2010-02-04 US disclosed
US-20100029647-A1 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES NOVARTIS AG (CH) 2010-02-04 US disclosed
WO-2006074924-A1 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES NOVARTIS AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029647-A1 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES REN, PAH, ACE ESR2 3709/4885NR1H2 3188/4885ABL1 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.